Blake Aftab

Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Agensys, Inc. develops a pipeline of therapeutic fully human monoclonal atibodies (mAbs) to treat cancer. It develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company was founded in 1997 and is headquartered in Santa Monica, CA.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

Alliance for Cancer Gene Therapy, Inc. provides funding for cancer research. The non-profit company is based in Stamford, CT. The company was founded by Edward Netter. Kevin Honeycutt has been the CEO of the company since 2018.

Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors.

Novalere, Inc. develops pharmaceutical products. The company is headquartered in Newton, MA.

Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA.

HSBC Bank Plc (Broker) (HSBC Bank-Broker) is the broker/dealer division of HSBC Bank Plc, which is owned by HSBC Holdings Plc (LON: HSBA; NYSE: HSBC) in Great Britain. Headquartered in London, HSBC Bank-Broker was founded in 1880 and offers bespoke brokerage services across every major asset class for their corporate and institutional clients.

Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022.

Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom.

The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members.

Abingworth Bioventures VI LP invests in private and public companies located the US and Europe. The fund targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, diagnostics and software. The fund provides financing for seed, early and late stage capital requirements with an investment size of $15 - $30 million. It seeks Majority or minority investments in the companies.

Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases.

Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions.

UCLA Technology Development Group (TDG) is an organization that promotes innovation, research, education, and entrepreneurship at UCLA. The private company is based in Los Angeles. The group works to translate UCLA's discoveries into new products and services that create economic value to support the university's scholarly and educational missions. TDG manages a large portfolio of technologies and license agreements and has a rich history of American startup company formation.

Yeda Research & Development Co. Ltd. engages in development of natural science and services. It covers broad of spectrum including: biotechnology, pharmaceuticals and diagnostics, bioinformatics, proteomics, biomatics and system biology, medical devices, renewable energy, bio fuels, clean technology and environmental sciences, agricultural and plants genetics, chemistry and nanotechnology, physics and electro-optics, mathematics and computer science. The company is headquartered in Rehovot, Israel.

Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D.

Dyve Biosciences, Inc. operates as a research and development company. It focuses on biotech that creates novel therapeutics using proprietary science. The company was founded by Ryan Beal and Rajit Malhotra and is headquartered in Thousand Oaks, CA.

cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel.

Dorian Therapeutics, Inc. operates as a anti-aging company that focusing on blocking the process of cellular senescence. The company was founded by Maddalena Adorno and Benedetta di Robilant and is headquartered in San Carlos, CA.

Shiprock Capital LLC (Shiprock Capital) is a venture capital firm founded in 1999 by Richard C. Shipley. The firm is headquartered in Wellesley, MA.